#	Pagina
attuale pagina	/open-h2020/projects/212666/index.html

Opendata, web and dolomites

PRESTIGE-AF SIGNED

PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

PRESTIGE-AF project word cloud

Explore the words cloud of the PRESTIGE-AF project. It provides you a very rough idea of what is the project "PRESTIGE-AF" about.

versus direct powered sufficiently perform genetics hierarchical settings therapy prevented sequential health survivors prevention bleeding disability personalize baseline hemorrhage estimate countries explore mortality size desirable gender ich antithrombotic ischemic centers packages generate attitudes economic prospective superior patient imbalances tool relevance individual individualized recurrence multidimensional oral causing stroke dilemma anticoagulants 662 intracerebral integrating adherence co regarding population recurrent balance strokes atrial trial biomarkers tailor subtype blinded rct generalizability blood biological unmet af prestige quality trials recruit reduces personalized primary first patients tools enrollment outcome replication randomized public prediction antiplatelet 20 model mri oac generally clinical data severe endpoint fibrillation benefits modeling outputs centered follow inferior uncertain risk societal expectancy life

Project "PRESTIGE-AF" data sheet

The following table provides information about the project.

Coordinator	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ website: http://www.imperial.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	6˙958˙896 €
EC max contribution	6˙958˙896 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2017-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-12-01 to 2022-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ website: http://www.imperial.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	coordinator	3˙332˙520.00
2	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WURZBURG postcode: 97080 website: www.uk-wuerzburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WURZBURG)	participant	1˙019˙373.00
3	FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA Organization address address: PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA city: BARCELONA postcode: 8035 website: http://www.vhir.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	468˙398.00
4	UNIVERSITATSKLINIKUM HEIDELBERG UNIVERSITATSKLINIKUM HEIDELBERG Organization address address: IM NEUENHEIMER FELD 672 city: HEIDELBERG postcode: 69120 website: www.klinikum.uni-heidelberg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HEIDELBERG)	participant	447˙700.00
5	MEDIZINISCHE UNIVERSITAT GRAZ MEDIZINISCHE UNIVERSITAT GRAZ Organization address address: AUENBRUGGERPLATZ 2 city: GRAZ postcode: 8036 website: http://www.medunigraz.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (GRAZ)	participant	343˙300.00
6	KING'S COLLEGE LONDON KING'S COLLEGE LONDON Organization address address: STRAND city: LONDON postcode: WC2R 2LS website: www.kcl.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	340˙000.00
7	UNIVERSITE DE BORDEAUX UNIVERSITE DE BORDEAUX Organization address address: PLACE PEY BERLAND 35 city: BORDEAUX postcode: 33000 website: www.nouvelle-univ-bordeaux.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (BORDEAUX)	participant	330˙609.00
8	JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG Organization address address: SANDERRING 2 city: WUERZBURG postcode: 97070 website: http://www.uni-wuerzburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WUERZBURG)	participant	283˙372.00
9	THE UNIVERSITY OF LIVERPOOL THE UNIVERSITY OF LIVERPOOL Organization address address: BROWNLOW HILL 765 FOUNDATION BUILDING city: LIVERPOOL postcode: L69 7ZX website: www.liverpool.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LIVERPOOL)	participant	116˙562.00
10	AZIENDA OSPEDALIERA DI PERUGIA AZIENDA OSPEDALIERA DI PERUGIA Organization address address: S ANDREA DELLE FRATTE city: PERUGIA postcode: 6156 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PERUGIA)	participant	115˙012.00
11	REGION NORDJYLLAND (NORTH DENMARK REGION) REGION NORDJYLLAND (NORTH DENMARK REGION) Organization address address: Niels Bohrs Vej 30 city: AALBORG postcode: 9220 website: www.rn.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (AALBORG)	participant	112˙500.00
12	STROKE ALLIANCE FOR EUROPE STROKE ALLIANCE FOR EUROPE Organization address address: RUE WASHINGTON 40 city: BRUSSELS postcode: 1050 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUSSELS)	participant	45˙000.00
13	THE UNIVERSITY OF BIRMINGHAM THE UNIVERSITY OF BIRMINGHAM Organization address address: Edgbaston city: BIRMINGHAM postcode: B15 2TT website: www.bham.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BIRMINGHAM)	participant	4˙547.00

Map

Project objective

Intracerebral hemorrhage (ICH) is a severe stroke subtype causing higher mortality and more disability than other strokes. 20% of ICH survivors have atrial fibrillation (AF), a major cause of ischemic stroke (IS). While IS in AF patients is generally prevented by oral anticoagulants (OAC), their use in ICH survivors is uncertain due to increased bleeding risk. No evidence from randomized controlled trials (RCT) is available addressing this dilemma. Personalized risk prediction is desirable to balance benefits of OAC against bleeding risk for individualized prevention.

Objectives: (1) To perform the first sufficiently powered RCT in ICH survivors with AF testing if direct OAC are superior for IS prevention and non-inferior regarding ICH recurrence versus antiplatelet or no antithrombotic therapy (2) To personalize antithrombotic prevention by multidimensional risk modeling (3) To estimate population impact of trial outputs on health economic consequences and generalizability to European population (4) To explore patient-centered aspects including adherence, attitudes towards antithrombotic therapy and gender imbalances in trial enrollment.

Methods: Prospective, open RCT with blinded outcome assessment. Hierarchical sequential testing of co-primary endpoint IS and recurrent ICH. Sample size: 662 patients. RCT will recruit in 70 centers in 6 countries over 2 years with 2 year follow-up. Clinical characteristics, MRI, blood-biomarkers and genetics will be characterized at baseline to model a new personalized risk prediction tool.

Relevance for work program: PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in ICH patients with AF. Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. Work packages integrating biological data will generate new tools to tailor prevention. Modeling of economic and societal consequences and replication in real-life settings will estimate population impact.

Deliverables

List of deliverables.
First study subject approvals package	Documents, reports	2020-03-24 00:29:29
Educational video onâ€œSample Collection Methods for Biomarker Studiesâ€	Websites, patent fillings, videos etc.	2020-03-24 00:29:29
PRESTIGE-AF â€œDissemination Packageâ€	Other	2020-03-24 00:29:29
Launch of website and social media accounts	Websites, patent fillings, videos etc.	2020-03-24 00:29:29
Dissemination & Communication Plan	Documents, reports	2020-03-24 00:29:29

Take a look to the deliverables list in detail: detailed list of PRESTIGE-AF deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRESTIGE-AF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRESTIGE-AF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More